Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The global chronic liver diseases therapeutics market is expected to witness significant growth during the forecast period owing to the increasing prevalence of liver disease. As the main reason causing cirrhosis is high consumption of alcohol. For instance, in 2015, according to the National Survey on Drug Use and Health (NSDUH) data, around 88,000 people (around 62,000 men and 26,000 women) died due to alcohol-related causes annually, which makes alcohol consumption the fourth leading preventable cause of death in the U.S.

Similarly, the high number of patients with chronic liver disease such as cirrhosis is contributing to the growth of the global chronic liver disease therapeutic market. For instance, in 2016, around 4.5 million adults were diagnosed with cirrhosis liver disease, out of which, 12.8 deaths occurred per 100,000 people. This is expected to drive growth of the global chronic liver disease therapeutics market. 

Global Chronic Liver Diseases Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic

The spread of coronavirus has negatively impacted the global chronic liver disease therapeutics market. The outbreak of this virus has hindered the growth of the global market. The U.S has the highest number of corona patients which is expected to impact the country’s economic condition. The U.S is high potential market for the pharmaceuticals industry, and the economic slowdown of the U.S economy is likely to impact the market for pharmaceutical drugs. Similarly, markets in India, Brazil, Russia and other economies are also suffering due to Covid-19 attack that is expected to impact on lowering the pharmaceutical growth.  Furthermore, due to COVID-19 pandemic, hospitals are closed in containment zones, that has slowed the hospital visits and stabilized the demand for therapeutic drugs of chronic liver diseases.

The global chronic liver diseases therapeutics market is estimated to be valued at US$ 12.8 Bn in 2020 and is expected to exhibit a CAGR of 9.7% during the forecast period (2020-2027).

Figure 1. Global Chronic Liver Diseases Therapeutics Market Share (%) Analysis in 2020, By Therapy Type

Chronic Liver Diseases Therapeutics  | Coherent Market Insights

Global Chronic Liver Diseases Therapeutics Market - Restraints

Side effects and risks associated with liver disease therapeutics are expected to hinder growth of the global liver disease therapeutics market. The side effects associated with the use of liver therapeutics are nausea, headache, fever loss of appetite, and drug-induced liver disease. Moreover, availability of alternate treatment procedures such as organ transplantation and liver resection are also expected to limit growth of the market.

request-sample

Chronic Liver Diseases Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 12.8 Bn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR:

9.7%

2027 Value Projection: US$ 24.9 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Therapy Type: Anti-Rejection Drugs/Immunosuppressant’s, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Immunoglobulin, Corticosteroids.
  • By Distribution Channel: Hospital Pharmacies , Retail Pharmacies, Online Pharmacies.
Companies covered:

Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.

Growth Drivers:
  • The increasing prevalence of liver cancer is expected to propel growth of the global liver diseases therapeutics market
Restraints & Challenges:
  • Side effects and risks associated with liver disease therapeutics are expected to hinder growth of the global liver disease therapeutics market

Global Chronic Liver Diseases Therapeutics Market: Opportunities

Increasing research and development of immunotoxins is expected to offer lucrative growth opportunities to players operating in the global chronic liver disease therapeutics market. For instance, GPC3 is a cell surface heparan sulfate proteoglycan that is overexpressed in hepatocellular carcinoma. Anti-GPC3 immunotoxins can be effective in the treatment of human hepatocellular carcinoma.

Moreover, clinical trials of new therapies are also expected to aid the market growth. For instance, in March 2018, the U.S. FDA granted Orphan Drug Designation for Protagonist Therapeutics, Inc.’s PTG-300; a subcutaneous injectable in clinical development stage for the potential treatment of beta-thalassemia and liver fibrosis.

Global Chronic Liver Diseases Therapeutics Market – Regional Analysis

On the basis of region, the global chronic liver disease therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

The market in North America is expected to witness significant growth owing to presence of major players in the region. Players are focused on collaboration strategies to expand their product portfolio. For instance, in April 2020, Alnylam Pharmaceuticals, Inc. collaborated with Dicerna Pharmaceuticals, Inc. for development and commercialization of investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease.

Asia Pacific is expected to witness significant growth during the forecast period owing to high disease prevalence in the region. For instance, according to the NCBI (National Center for Biotechnology Information), Asia Pacific accounted for 62.6% of global deaths due to liver disease in 2015.

Europe is also expected to witness growth in the global chronic liver disease therapeutics market owing to increased number of liver diseased population in European countries. For instance, according to data published by the UK Research Alcohol Association in 2017, around 7,700 people die from alcohol-related liver disease each year in the U.K.

Figure 2. Global Chronic Liver Diseases Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Chronic Liver Diseases Therapeutics  | Coherent Market Insights

Global Chronic Liver Diseases Therapeutics Market - Competitive Landscape

Key players operating in the global chronic liver disease therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.

The liver is the largest organ of the body which performs a wide variety of roles that include converting food into energy, creating bile for proper digestion of food, and detoxifying alcohol and poison from the blood. There are several kinds of liver diseases such as hepatitis A, hepatitis B, and hepatitis C; liver fibrosis, liver cancer; fatty liver disease and cirrhosis; hemochromatosis, and Wilson’s disease.

However, side effects and risks associated with liver disease therapeutics are expected to hinder growth of the global chronic liver disease therapeutics market. The side effects associated with the use of liver therapeutics are nausea, headache, fever loss of appetite, and drug-induced liver disease. Moreover, availability of alternate treatment procedures such as organ transplantation and liver resection are also expected to limit growth of the market.

Market Dynamics

The increasing research and development activities are expected to drive the market growth in the near future. For instance, in March 2020, MAX BioPharma, Inc. announced the efficacy of its anti-tumorigenic oxysterol lead compound, Oxy210, in the treatment of liver fibrosis.

Similarly, in April 2020, Provectus Biopharmaceuticals Inc.’s data from its clinical trial of autolytic cancer immunotherapy PV-10 (rose bengal disodium) as a single-agent and in combination with immune checkpoint blockade for the treatment of primary or metastatic tumors of the liver was uploaded to the SIR 2020 ePoster Gallery of the cancelled Society of Interventional Radiology 2020 Annual Scientific Meeting.

Additionally, focus of research institutes on developing novel therapies to treat chronic liver diseases is expected to drive growth of this market during the forecast periods. For instance, in 2019, the U.S based Virginia Commonwealth University conducted Phase III clinical trial of a drug for treating non-alcoholic steatohepatitis (NASH), a chronic liver disease.

Key features of the study:

  • This report provides in-depth analysis of the global chronic liver disease therapeutics market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global chronic liver diseases therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study are Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global chronic liver diseases therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for global chronic liver diseases therapeutics market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Chronic Liver Diseases Therapeutics Market, By Therapy Type:
    • Anti-Rejection Drugs/Immunosuppressants
    • Chemotherapy Drugs
    • Targeted therapy
    • Vaccines
    • Anti-Viral Drugs
    • Immunoglobulins
    • Corticosteroids
  • Global Chronic Liver Diseases Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Chronic Liver Diseases Therapeutics Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Therapy:
        • Anti-Rejection Drugs/Immunosuppressants
        • Chemotherapy Drugs
        • Targeted therapy
        • Vaccines
        • Anti-Viral Drugs
        • Immunoglobulins
        • Corticosteroids
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Therapy:
        • Anti-Rejection Drugs/Immunosuppressants
        • Chemotherapy Drugs
        • Targeted therapy
        • Vaccines
        • Anti-Viral Drugs
        • Immunoglobulins
        • Corticosteroids
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Therapy:
        • Anti-Rejection Drugs/Immunosuppressants
        • Chemotherapy Drugs
        • Targeted therapy
        • Vaccines
        • Anti-Viral Drugs
        • Immunoglobulins
        • Corticosteroids
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Therapy:
        • Anti-Rejection Drugs/Immunosuppressants
        • Chemotherapy Drugs
        • Targeted therapy
        • Vaccines
        • Anti-Viral Drugs
        • Immunoglobulins
        • Corticosteroids
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Therapy:
        • Anti-Rejection Drugs/Immunosuppressants
        • Chemotherapy Drugs
        • Targeted therapy
        • Vaccines
        • Anti-Viral Drugs
        • Immunoglobulins
        • Corticosteroids
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Therapy:
        • Anti-Rejection Drugs/Immunosuppressants
        • Chemotherapy Drugs
        • Targeted therapy
        • Vaccines
        • Anti-Viral Drugs
        • Immunoglobulins
        • Corticosteroids
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Astellas Pharma Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Bristol-Myers Squibb
    • Gilead Sciences
    • GlaxoSmithKline Plc
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co. Inc.
    • Novartis AG
    • Sanofi S.A
    • Pfizer Inc.
    • Takeda Pharmaceutical
    • Valeant Pharmaceuticals
    • Watson Pharmaceuticals, Inc.
    • Theratechnologies Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Protagonist Therapeutics, Inc.
    • Dicerna Pharmaceuticals, Inc.
    • Endo International
    • Provectus Biopharmaceuticals Inc.
    • MAX BioPharma, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Therapy Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Market Trends
    • Key Developments
    • Impact Analysis
    • Regulatory Scenario
    • Reimbursement Scenario
    • New Drug Launches/Approvals
    • Mergers & Acquisitions
    • PEST Analysis
  4. Global Chronic Liver Diseases Therapeutics Market, by COVID-19 impact analysis
    • Pre COVID Impact
    • Post COVID Impact
    • Government Initiative
  5. Global Chronic Liver Diseases Therapeutics Market, By Therapy Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Anti-Rejection Drugs/ Immunosuppressants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Chemotherapy Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Targeted therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Anti-Viral Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Immunoglobulins
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Chronic Liver Diseases Therapeutics Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Chronic Liver Diseases Therapeutics Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Therapy Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Therapy Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Therapy Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Therapy Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Therapy Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Therapy Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Company Profiles
      • Astellas Pharma Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bristol-Myers Squibb
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Gilead Sciences
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GlaxoSmithKline Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Hoffmann-La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck & Co. Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Takeda Pharmaceutical
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Valeant Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Watson Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Theratechnologies Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Alnylam Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Protagonist Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Dicerna Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Endo International
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Provectus Biopharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • MAX BioPharma, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 34 market data tables and 30 figures on "Global Chronic Liver Disease Therapeutics Market” - Forecast to 2027”

Frequently Asked Questions

The global chronic liver disease therapeutics market is expected to register a CAGR of 9.7% during the forecast period (2020-2027).
The market value of the global chronic liver disease therapeutics market is estimated to be US$ 12.8 billion in 2020.
The prominent players in the global chronic liver disease therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
The Chronic Liver Disease Therapeutics Market is expected to be valued at US$ 24.9 billion in 2027.
North America is a major region in the global chronic liver disease therapeutics market.
Approval and launch of novel therapies for treatment of liver diseases is expected to propel growth of the global liver diseases therapeutics market during the forecast period. Similarly, the extensive R&D expenditure by pharmaceutical and biotechnology companies is expected to propel the global liver disease therapeutics market growth during the forecast period.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner